triple agonist glp-1 History of glucagon-like peptide-1 receptor agonists GLP-1-based therapies for type 2

No wonder payers are concerned about the short- and long-term costs

Real-world results vary based on dose, adherence, diet, activity level, and individual biology

And it should, because safety data often matters more than efficacy data for individual treatment decisions

A 2025 study reported evidence of telomere length stabilization or modest lengthening, raising the possibility that metabolic therapies may influence pathways related to genomic stability and replicative lifespan [16]

The study found that 3.6 million people (14.2% of Medicare beneficiaries) were highly likely to be eligible for Wegovy coverage if Medicare used a more conservative definition of established cardiovascular disease, and up to 15.2 million people (60.9% of beneficiaries) could be eligible if Medicare went with a more liberal definition

Eur Psychiatry